NCT00645073View on ClinicalTrials.gov

Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis

PHASE4CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

March 31, 2004

Conditions
Acute Bacterial Sinusitis
Interventions
DRUG

cefdinir (Omnicef)

Two 300 mg cefdinir capsules on Study Days 1-10.

DRUG

levofloxacin

Two 250 mg levofloxacin capsules on Study Days 1-10

Trial Locations (33)

22601

Winchester

29118

Orangeburg

35051

Columbiana

35211

Birmingham

35215

Birmingham

35406

Tuscaloosa

36024

Eclectic

37660

Kingsport

38358

Milan

42071

Murray

49024

Portage

75110

Corsicana

78205

San Antonio

84084

West Jordan

84088

West Jordan

84109

Salt Lake City

84121

Salt Lake City

85201

Mesa

93703

Fresno

93710

Fresno

97035

Lake Oswego

97404

Eugene

99204

Spokane

66-400

Gorzów Wielkopolski

30-510

Krakow

31-513

Krakow

90-430

Lodz

92-215

Lodz

322-088

Przybysławice

96-100

Skierniewice

70-344

Szczecin

70-506

Szczecin

71-667

Szczecin

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00645073 - Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis | Biotech Hunter | Biotech Hunter